Email Updates

You are here

25 JUNE 2021 VOLUME 23 ISSUE 25

Media Coverage

  • Emergency departments and inpatient medical personnel rarely conducted HIV testing on intravenous drug users in a West Virginia county with one of the nation’s highest spikes in such cases, according to a federal investigation released Thursday.

    June 24, 2021
    General
    AP
  • Long-acting formulations are being developed to overcome barriers—primarily, adherence—presented by daily oral therapy. Encouraging results regarding adherence comes from the phase IIb LATTE-2 study (NCT02120352) evaluating long-acting cabotegravir-rilpivirine for HIV treatment where 99 percent of participants preferred to continue with injectable therapy compared with 78 percent on oral treatment. The purpose of this article is to provide an overview of the various ART therapies being studied and are available for prevention and treatment of HIV.

    June 24, 2021
    Contagion Live
  • The COVID-19 lockdown has negatively affected South Africa’s medical circumcision programme and far fewer men have been circumcised in the past year than in previous years, health NGO Right to Care reported.

    June 23, 2021
    Talk of the Town
  • For half a decade, longtime US health official Deborah Birx, MD, presided—powerfully and effectively, by broad accounts—over a program known as PEPFAR. That’s the acronym for the US President’s Emergency Plan for AIDS Relief, which was started in 2003 by President George W. Bush with the goal of bringing lifesaving HIV treatment and other tools to the world’s poorest, most AIDS-afflicted countries.

    June 21, 2021
    General
    The Body
  • Countries that criminalise same-sex relationships, sex work and drug use have significantly more people with undiagnosed HIV and lower rates of viral suppression than countries that do not criminalise, or criminalise these areas to a lesser extent. Countries with human rights protections in place fared much better than those without on these HIV-related indicators, according to an analysis by Dr Matthew Kavanagh of Georgetown University. It has been published as a pre-print and has not yet been reviewed by other scientists.

    June 21, 2021
    General
    aidsmap
  • The thought of robots taking over our jobs—and doing them better than we ever could—isn’t always a particularly welcoming thought. One major exception is when artificial intelligence software can analyze rapid diagnostic tests with near-perfect accuracy in under-resourced areas, using only a standard smartphone.

    June 21, 2021
    General
    Fierce Biotech
  • When peer HIV testers explained the science behind Undetectable Equals Untransmittable (U=U), men were 89 percent more likely to agree to be tested for the virus, according to a pilot study published in AIDS and Behavior.

    June 21, 2021
    POZ
  • In a major milestone that will curb pill fatigue and reduce default cases, Zimbabwe will among other countries introduce a new HIV preventive drug that will be taken only once a month.

    June 20, 2021
    Bulawayo 24 News
  • Australian advocacy organisations and researchers have called on the government to set a new goal to end HIV transmission in the country in four short years. The new path to end transmission, comes on the 40th anniversary of the first reported case of HIV. The organisations said that the goal can be achieved with a surprisingly modest budget – but only if the Australian government adopts and implements the plan.

    June 20, 2021
    General
    Star Observer
  • Last August, the Journal of the American Heart Association (JAHA) published an article by University of Pittsburgh cardiologist Norman Wang, MD, that accused educational affirmative action programs of sending ill-qualified Black and Hispanic trainees to some of the top medical schools in the country. Soon after its publication, the article was retracted and denounced as both racist and factually inaccurate.

    June 17, 2021
    General
    The BodyPro
  • GlaxoSmithKline PLC’s unit ViiV Healthcare said on Monday its two-drug regimen to treat HIV was as effective in patients given the treatment every two months, as when administered once a month. The drug, Cabenuva, the long-acting injectable two-drug regimen of antiviral compounds cabotegravir and Johnson & Johnson’s rilpivirine, met the main goal at the end of 48 weeks.

    March 9, 2020
    Reuters

Published Research

Announcements